Antagonists of HMG1 for treating inflammatory conditions

Details Antagonists of HMG1 for treating inflammatory conditions Antagonists of HMG1 for treating inflammatory conditions

2009-04-13

2011-11-08

Spector, Lorraine (Department: 1649)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C424S139100, C436S501000

Reexamination Certificate

active

08053206

ABSTRACT:
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.

REFERENCES:
patent: 4678772 (1987-07-01), Segal et al.
patent: 4835142 (1989-05-01), Suzuki et al.
patent: 4871740 (1989-10-01), Kurono et al.
patent: 5229378 (1993-07-01), Ogata et al.
patent: 5425948 (1995-06-01), Olivieri
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5852174 (1998-12-01), Vlassara et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 6171779 (2001-01-01), Chada et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6329339 (2001-12-01), Pompei et al.
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 6468555 (2002-10-01), Nakamura
patent: 6677321 (2004-01-01), Levin
patent: 6720472 (2004-04-01), Chada et al.
patent: 6783961 (2004-08-01), Edwards et al.
patent: 6822078 (2004-11-01), Ozaki et al.
patent: 7060504 (2006-06-01), Tracey et al.
patent: 7097838 (2006-08-01), Tracey et al.
patent: 7151082 (2006-12-01), Tracey et al.
patent: 7192917 (2007-03-01), Tracey et al.
patent: 7220723 (2007-05-01), Tracey et al.
patent: 7230078 (2007-06-01), Schiffrin et al.
patent: 7288250 (2007-10-01), Newman et al.
patent: 7304034 (2007-12-01), Tracey et al.
patent: 7537908 (2009-05-01), Tracey et al.
patent: 7572446 (2009-08-01), Traccy et al.
patent: 7632500 (2009-12-01), Newman et al.
patent: 7696169 (2010-04-01), Tracey et al.
patent: 7749959 (2010-07-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2002/0122799 (2002-09-01), Stern et al.
patent: 2002/0193432 (2002-12-01), Mjalli et al.
patent: 2003/0027260 (2003-02-01), Gooddard et al.
patent: 2003/0032090 (2003-02-01), Hardiman et al.
patent: 2003/0032674 (2003-02-01), Hwang
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 2004/0005316 (2004-01-01), Tracey et al.
patent: 2004/0141948 (2004-07-01), O'Keefe
patent: 2006/0240019 (2006-10-01), Tracey et al.
patent: 2007/0238640 (2007-10-01), Tracey et al.
patent: 2008/0113385 (2008-05-01), Newman et al.
patent: 2008/0167234 (2008-07-01), Tracey et al.
patent: 2008/0214454 (2008-09-01), Tracey et al.
patent: 2009/0148453 (2009-06-01), Newman et al.
patent: 2010/0040608 (2010-02-01), Wahren-Herlenius et al.
patent: 2002247977 (2002-03-01), None
patent: 0 552 439 (1993-07-01), None
patent: 1 079 849 (2002-01-01), None
patent: 1 165 110 (2006-05-01), None
patent: 1 757 937 (2007-02-01), None
patent: 1 757 937 (2007-04-01), None
patent: 2137125 (1999-12-01), None
patent: 62-166897 (1987-07-01), None
patent: 10082788 (1998-03-01), None
patent: 2003 096099 (2003-04-01), None
patent: 2004 523579 (2004-08-01), None
patent: WO 96/25493 (1996-08-01), None
patent: WO 97/23611 (1997-07-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 00/20621 (2000-04-01), None
patent: WO 00/47104 (2000-08-01), None
patent: WO 00/55174 (2000-09-01), None
patent: WO 00/75358 (2000-12-01), None
patent: WO 01/72993 (2001-04-01), None
patent: WO 01/36488 (2001-05-01), None
patent: WO 01/55386 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/90151 (2001-11-01), None
patent: WO 01/99210 (2001-12-01), None
patent: WO 02/069965 (2002-09-01), None
patent: WO 02/070007 (2002-09-01), None
patent: WO 02/074301 (2002-09-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/089743 (2002-11-01), None
patent: WO 02/090520 (2002-11-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 03/022296 (2003-03-01), None
patent: WO 03/075921 (2003-09-01), None
patent: WO 2004/004763 (2004-01-01), None
patent: WO 2004/046345 (2004-06-01), None
patent: WO 2005/026209 (2005-03-01), None
patent: WO 2006/024547 (2006-03-01), None
patent: WO 2007/011606 (2007-01-01), None
patent: WO 2007/076200 (2007-07-01), None
patent: WO 2008/076758 (2008-06-01), None
Blank, M., et al., “Immunization With Anti-Neutrophil Cytoplasmic Antibody (ANCA) Induces the Production of Mouse ANCA and Perivascular Lymphocyte Infiltration,”Clin. Exp. Immunol. 102:120-130 (1995).
Brennan, F.M., et al.. “Role of Pro-Inflammatory Cytokines in Rheumatoid Arthritis,”Springer Semin. Immunopathol. 20:133-147 (1998).
Davidson, N.J., “The Therapeutic Potential of Anti-Cytokine Antibodies in the Treatment of Chronic Inflammatory Disease,”Exp. Opin. Invest. Drugs7(7):1115-1120 (1998).
Di Carlo, E., et al., “Interaction Between Endothelial Cells and the Secreted Cytokine Drives the Fate of an IL4- or an IL5-Transduced Tumour,”J. Pathol. 186:390-397 (1998).
Ekström, P.A.R., et al., “The Immune Modulator Linomidc Prevents Neuronal Death in Injured Peripheral Nerves of the Mouse,”NeuroReport9(7):1337-1341 (1998).
Elkarim, R.A., et al., “Recovery From Guillain-Barré Syndrome is Associated With Increased Levels of Neutralizing Autoantibodies to Interferon-γ,”Clinical Immunology and Immunopathology88(3):241-248 (1998).
Fallon, M.T. and Hanks, G.W., “Control of Common Symptoms in Advanced Cancer,”Ann. Acad. Med. Singapore23(2):171-177 (1994).
“FDA Approves New Kind of Lymphoma Treatment,”AIDS Treatment News, 1997.
Gonzalez, E.R., and Kannewurf. B.S., “Atherosclerosis: A Unifying Disorder With Diverse Manifestations,”Am. J. Health-Syst. Pharm. 55(Suppl 1):S4-S7 (1998).
Heeringa, P., et al., “Autoantibodies to Myeloperoxidase Aggravate Mild Anti-Glomerular-Basement-Membrane-Mediated Glomerular Injury in the Rat,”Am. J. Pathol. 149(5):1695-1706 (1996).
Hermann, J., et al., “Cytokine Therapy in Rheumatoid Arthritis,”Springer Semin Immunopathol20:275-288 (1998).
Janeway, Jr., C.A., et al. Immuno Biology the Immune System in Health and Disease, 3rdEd. Garland Publishing Inc. pp. 2:9 and 2:23 (1997).
Jayne, D.R.W., et al., “ANCA Anti-Idiotype Antibodies and the Treatment of Systemic Vasculitis With Intravenous Immunoglobulin,”J. Autoimmunity6:207-219 (1993).
Jorens, P.G., et al., “High Levels of Leukaemia Inhibitory Factor in ARDS,”Cytokine8(11):873-876 (1996).
Jouvenne, P., et al., “Increased Incidence of Neutralizing Autoantibodies Against Interleukin-1α (IL-1α) in Nondestructive Chronic Polyarthritis,”J. Clin. Immunol. 16(5):283-290 (1996).
Kobayashi, K., et al., “Aggravation of Rat Nephrotoxic Serum Nephritis by Anti-Myeloperoxidase Antibodies,”Kidney International47:454-463 (1995).
Li, J., et al. “Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1,”Molecular Medicine9:37-45 (2003).
Miyata, T., et al., “The Receptor for Advanced Glycation End Products (RAGE) is a Central Mediator of the Interaction of AGE-β2Microglobulin With Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway,”J. Clin. Invest. 98(5):1088-1094 (1996).
Sioud, M., et al., “Characterization of Naturally Occurring Autoantibodics Against Tumour Necrosis Factor-alpha (TNF-α): in vitro function and Precise Epitope Mapping by Phage Epitope Library,”Clin. Exp. I

Affiliated with

Also associated with

Rating

Antagonists of HMG1 for treating inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists of HMG1 for treating inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of HMG1 for treating inflammatory conditions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4284256